Evidence map›Paper›PMID 42252453›Full record

ArticleCell & bioscience2026

A segregating PTK2B variant in a primary biliary cholangitis (PBC) family induces PBC-like autoimmune features in knock-in mice.

Sainan Bian, Yanlei Yang, Zhilei Chen, Li Wang, Hua Chen, Suying Liu, Chengmei He, Yongzhe Li, Xue Zhang, Fengchun Zhang

Abstract read
In one paragraph

Article in Cell & bioscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Sainan Bian *Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Yanlei Yang *Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Zhilei Chen *Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Li WangDepartment of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Hua ChenDepartment of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Suying LiuDepartment of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Chengmei HeDepartment of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Yongzhe LiDepartment of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Xue ZhangMcKusick-Zhang Center for Genetic Medicine, State Key Laboratory of Medical Molecular Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. xuezhang@pumc.edu.cn.
Fengchun ZhangDepartment of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. zhangfccra@aliyun.com.

Funding

CAMS Innovation Fund for Medical Sciences (CIFMS) 2025-I2M-XHXX-017National Key Research and Development Program of China 2016YFA0101003National Natural Science Foundation of China 81771764National Natural Science Foundation of China 82300981New Drug Clinical Evaluation Research Technology Platform for Autoimmune Diseases, Diabetes, and Osteoporosis FM091401Peking Union Medical College Hospital Talent Cultivation Program Category D UHB11951
6 · The paper itself

Abstract

backgroundPrimary biliary cholangitis (PBC) is a chronic autoimmune cholestatic liver disease with an incompletely understood genetic basis. This study aimed to identify disease-causing genetic variants in a PBC family and to evaluate their functional relevance in vivo.

resultsA total of 27 family members were enrolled in the analysis, among whom three were affected. After filtering of the whole-exome sequencing results of the PBC family, 17 candidate variants were identified, among which a protein tyrosine kinase 2β (PTK2B) c.1679C > G variant exclusively co-segregated with PBC in affected family members and was absent in unaffected relatives, healthy controls, and public databases. Homozygous knock-in mice exhibited significantly elevated serum alkaline phosphatase (236 ± 55 vs. 142 ± 43 U/L, P = 0.01) and antimitochondrial antibody levels (3924 ± 769 vs. 1972 ± 632 U/mL, P = 0.001) compared with heterozygous mice, along with portal lymphocytic infiltration, intrahepatic bile duct proliferation, and liver fibrosis. Female homozygous knock-in mice showed increased hepatic infiltration of CD3

conclusionsThis study identifies a segregating PTK2B variant in a family with PBC and demonstrates that the corresponding knock-in mutation induces PBC-like autoimmune features in mice. These findings provide human genetic and in vivo evidence supporting PTK2B as a candidate susceptibility gene for PBC.

Indexed as

Exome sequencingMouse modelPBCPrimary biliary cholangitisPTK2B

Identifiers

PMID42252453
PMCPMC13465097

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.